FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4251036998> ?p ?o ?g. }

• W4251036998 endingPage "2547" @default.
• W4251036998 startingPage "2547" @default.
• W4251036998 abstract "2547 Background: Theratope is an investigational therapeutic cancer vaccine consisting of a synthetic form of STn conjugated to KLH. Phase III study results showed a trend for increased survival in MBC pts concurrently treated with Theratope (T) and hormone therapy (HT) (38.2mo (T) vs. 30.7mo (control, C), Cox P= 0.07). Methods: MBC pts with no evidence of disease or non-progressive disease following any first-line chemotherapy were eligible for a randomized, controlled, double-blind, multicenter study. Study arms were adjuvant plus T or adjuvant plus KLH (C). All pts received a single IV dose of cyclophosphamide (300mg/m2) 72 hr before vaccine. Primary endpoints were overall survival (OS) and time to progression. Secondary endpoints were humoral (IgG) responses to the KLH (carrier), STn (synthetic monomeric form), and OSM (naturally occurring clustered STn) antigens in MBC pts +/- HT treated with T. IgG was measured using ELISA assays for STn, OSM, and KLH at week-12 of vaccine therapy. Median OS was prospectively assessed as a function of IgG titers. Results: Of a planned accrual of 950 pts, 1030 were enrolled and 1028 randomized to recive adjuvant + T(n=523) or C (n=505). As of September 2003, median duration of follow-up was 22.2 mo. Median titer of anti-OSM IgG was 320 in the T group and 0 in the C group. Median OS was significantly greater in T treated pts who received concurrent HT and who had IgG titers of anti-OSM equal to or higher than the median titer (41.1 vs. 25.4 mo, log-rank p=0.01) (see Table). OS was not influenced by anti-STn or anti-KLH titers, indicating that only titers of the naturally occurring clustered STn antigen are predictive of increased OS. Conclusions: Experimental vaccine trials suggest that the ability to mount an immune response is associated with favorable clinical outcomes. Our data from this large, prospective trial indicate that the magnitude of the immune response to the relevant and specific antigen is most predictive of a favorable clinical outcome. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Biomira, Inc.; EMD Pharmaceuticals Biomira, Inc. Biomira, Inc.; EMD Pharmaceuticals Biomira, Inc.; Merck KGaA" @default.
• W4251036998 created "2022-05-12" @default.
• W4251036998 creator A5013741866 @default.
• W4251036998 creator A5058485964 @default.
• W4251036998 creator A5061322428 @default.
• W4251036998 creator A5077026571 @default.
• W4251036998 creator A5085796222 @default.
• W4251036998 date "2004-07-15" @default.
• W4251036998 modified "2023-09-26" @default.
• W4251036998 title "Humoral immune-response to naturally occurring STn in metastatic breast cancer patients (MBC pts) treated with STn-KLH vaccine" @default.
• W4251036998 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.2547" @default.
• W4251036998 hasPublicationYear "2004" @default.
• W4251036998 type Work @default.
• W4251036998 citedByCount "6" @default.
• W4251036998 countsByYear W42510369982019 @default.
• W4251036998 crossrefType "journal-article" @default.
• W4251036998 hasAuthorship W4251036998A5013741866 @default.
• W4251036998 hasAuthorship W4251036998A5058485964 @default.
• W4251036998 hasAuthorship W4251036998A5061322428 @default.
• W4251036998 hasAuthorship W4251036998A5077026571 @default.
• W4251036998 hasAuthorship W4251036998A5085796222 @default.
• W4251036998 hasConcept C121608353 @default.
• W4251036998 hasConcept C126322002 @default.
• W4251036998 hasConcept C159654299 @default.
• W4251036998 hasConcept C168563851 @default.
• W4251036998 hasConcept C203014093 @default.
• W4251036998 hasConcept C203092338 @default.
• W4251036998 hasConcept C2775930923 @default.
• W4251036998 hasConcept C2776694085 @default.
• W4251036998 hasConcept C2776755627 @default.
• W4251036998 hasConcept C2777863537 @default.
• W4251036998 hasConcept C32611913 @default.
• W4251036998 hasConcept C530470458 @default.
• W4251036998 hasConcept C71924100 @default.
• W4251036998 hasConcept C90924648 @default.
• W4251036998 hasConceptScore W4251036998C121608353 @default.
• W4251036998 hasConceptScore W4251036998C126322002 @default.
• W4251036998 hasConceptScore W4251036998C159654299 @default.
• W4251036998 hasConceptScore W4251036998C168563851 @default.
• W4251036998 hasConceptScore W4251036998C203014093 @default.
• W4251036998 hasConceptScore W4251036998C203092338 @default.
• W4251036998 hasConceptScore W4251036998C2775930923 @default.
• W4251036998 hasConceptScore W4251036998C2776694085 @default.
• W4251036998 hasConceptScore W4251036998C2776755627 @default.
• W4251036998 hasConceptScore W4251036998C2777863537 @default.
• W4251036998 hasConceptScore W4251036998C32611913 @default.
• W4251036998 hasConceptScore W4251036998C530470458 @default.
• W4251036998 hasConceptScore W4251036998C71924100 @default.
• W4251036998 hasConceptScore W4251036998C90924648 @default.
• W4251036998 hasIssue "14_suppl" @default.
• W4251036998 hasLocation W42510369981 @default.
• W4251036998 hasOpenAccess W4251036998 @default.
• W4251036998 hasPrimaryLocation W42510369981 @default.
• W4251036998 hasRelatedWork W1539989077 @default.
• W4251036998 hasRelatedWork W2031329688 @default.
• W4251036998 hasRelatedWork W2035712195 @default.
• W4251036998 hasRelatedWork W2056987309 @default.
• W4251036998 hasRelatedWork W2147292731 @default.
• W4251036998 hasRelatedWork W2298028778 @default.
• W4251036998 hasRelatedWork W2365277249 @default.
• W4251036998 hasRelatedWork W2380201224 @default.
• W4251036998 hasRelatedWork W4214554217 @default.
• W4251036998 hasRelatedWork W2427250343 @default.
• W4251036998 hasVolume "22" @default.
• W4251036998 isParatext "false" @default.
• W4251036998 isRetracted "false" @default.
• W4251036998 workType "article" @default.